바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.62 No.4
Citation Share

Tuberculin Skin Test and QuantiFERON-TB Gold Assay before and after Treatment for Latent Tuberculosis Infection among Health Care Workers in Local Tertiary Hospital

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2007, v.62 no.4, pp.270-275











& (2007). Tuberculin Skin Test and QuantiFERON-TB Gold Assay before and after Treatment for Latent Tuberculosis Infection among Health Care Workers in Local Tertiary Hospital. Tuberculosis & Respiratory Diseases, 62(4), 270-275.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: The QuantiFERON-TB Gold assay and tuberculin skin test (TST) have been useful test for diagnosing latent tuberculosis infections (LTBI). However, there are few reports on the efficacy of the QuantiFERON-TB Gold assay and TST in evaluating the response after the treatment of LTBI. This study examined the changes in the TST and QuantiFERON-TB Gold assay before and after a treatment for latent tuberculosis in health care workers (HCWs) at a local tertiary hospital. Methods: A cohort of volunteers working as nurses and doctors who underwent a TST and QuantiFERON-TB Gold assay was established. The volunteers positive for the QuantiFERON-TB Gold assay had been treated with 3 months of isoniazid (INH) and rifampin (RFP). After completing treatment, the TST and QuantiFERON-TB Gold assay were repeated. Results: Of the 48 participants (14 doctors, 34 nurses, M: F=11:37, mean age=29.9±5.5 years, mean employment period=74.9±64.3 months), 19 (39.6%) tested positive to the TST (mean induration=19.1±9.7 mm) and 8 (16.7%) were QuantiFERON-TB Gold assay. Among them, one had active pulmonary tuberculosis. Seven volunteers were consistently positive to both the TST and QuantiFERON-TB Gold assay after being medicated with INH and RFP for 3 months. Conclusion: TST and QuantiFERON-TB Gold assay are unsuitable for evaluating the treatment response of LTBI because they were consistently positive both before and after the anti-tuberculosis medication. (Tuberc Respir Dis 2007; 62: 270-275)

keywords
Latent tuberculosis infection (LTBI), Treatment, Tuberculin skin test (TST), QuantiFERON-TB Gold assay, Health care workers., Latent tuberculosis infection (LTBI), Treatment, Tuberculin skin test (TST), QuantiFERON-TB Gold assay, Health care workers.

Reference

1.

(1999) Consensus statement: global burden of tuberculosis: estimated incidence, prevalence, and mortality by country: WHO Global Surveillance and Monitoring Project,

2.

(2004) Diagnosis and treatment of latent tuberculosis infection in Korea,

3.

(2001) Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians,

4.

(2004) Comparison of a new specific blood test and the skin test in tuberculosis contacts,

5.

(2004) Specific detection of tuberculosis infection an interferon-gamma based assay using new antigens,

6.

(2001) Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection,

7.

(2002) Evaluation of a whole blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations,

8.

(2005) Discrepancy between the tuberculin skin test and the whole-blood interferon assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country,

9.

(2006) Persistently elevated T cell interferon-γ responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report,

10.

(2005) Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole blood, interferon-g assay with tuberculin skin testing,

11.

(2003) Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection,

12.

(2000) Effect of anti-tuberculosis treatment on the tuberculin interferon-gamma response in tuberculin skin test (TST) positive health care workers and patients with tuberculosis,

13.

(2001) Direct ex vivo analysis of antigen-specific IFN-gamma secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment,

14.

(2002) Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii,

15.

(2000) Control and prevention of tuberculosis in the United Kingdom: code of practice 2000,

16.

(amrevrespirdis1992;145) A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong,

17.

(1998) Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis,

18.

(1997) A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus,

19.

(2000) Anti-Tuberculosis Drug Resistance in the World,

20.

(2002) Treatment of isoniazid resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months,

21.

(2002) Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis,

22.

(2002) Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy